Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806368 | 0.85 | LMNA (0.52) | PPARGSMN1; SMN2ALDH1A1PPARAOPRK1 | |
| SCHEMBL2806027 | 0.83 | PPARG (0.84) | PPARGALDH1A1PPARA | |
| SCHEMBL2809038 | 0.83 | PPARG (0.84) | PPARGALDH1A1PPARA | |
| SCHEMBL2811651 | 0.83 | PPARG (0.84) | PPARGALDH1A1PPARA | |
| SCHEMBL2809240 | 0.83 | PPARG (0.69) | PPARGSMN1; SMN2RAB9AALDH1A1PPARA | |
| SCHEMBL2807754 | 0.78 | PPARG (0.70) | PPARGALDH1A1PPARA | |
| SCHEMBL2804981 | 0.75 | OPRK1 (0.51) | PPARGALDH1A1PPARAOPRK1 | |
| SCHEMBL5116975 | 0.75 | OPRK1 (0.51) | PPARGALDH1A1PPARAOPRK1 | |
| SCHEMBL5118505 | 0.75 | OPRK1 (0.51) | PPARGALDH1A1PPARAOPRK1 | |
| SCHEMBL2804812 | 0.75 | PPARG (0.69) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513233-B2 | Pyrimidinyl-propionic acid derivatives and their use as PPAR agonists | SHANGHAI INSTITUTE OF MATERIA MEDICA, CAS (CN) | 2013-08-20 | — | — | US | disclosed |
| US-20100240636-A1 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | SHENYANG SUNSHINE PHARMACEUTICAL COMPANY LIMITED (CN) | 2010-09-23 | — | — | US | disclosed |
| WO-2009046606-A1 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | SHANGHAI INSTITUTE OF MATERIA MEDICA, CAS (CN) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240636-A1 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | PPARA, PPARD, PPARG | PPARG 3/4885SMN1; SMN2 4849/4885RAB9A 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.